Journal article
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐TNF‐α naïve Crohn's disease
Abstract
BACKGROUND: TNFα antagonists, including infliximab (IFX) and adalimumab (ADA), have revolutionised treatment for Crohn's disease. Studies comparing efficacy in patients with Crohn's disease naïve to TNFα antagonists are lacking.
METHODS: Consecutive TNFα antagonist-naïve patients with luminal or perianal Crohn's disease from four tertiary centres in Austria were assessed prospectively for induction and maintenance efficacy, and safety, of …
Authors
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Journal
Alimentary Pharmacology & Therapeutics, Vol. 44, No. 2, pp. 170–180
Publisher
Wiley
Publication Date
July 2016
DOI
10.1111/apt.13671
ISSN
0269-2813